Background: STEMI is a clinical syndrome defined by characteristic symptoms of myocardial ischemia in association with persistent
electrocardiographic (ECG) ST elevation and subsequent release of biomarkers of myocardial necrosis.
Aim of the Study: Was to detect efficacy and predictors of outcomes of pharmacoinvasive treatment strategy in STEMI patients over
reperfusion with thrombolysis only in areas with non-PCI capable centers as in most of hospitals in middle east.
Methods and Results: A time limited prospective interventional study started in November 2016 till November 2018. Patients
divided into two groups, first group 300 patients treated with Lysis full dose TNK followed by risk stratification, the other 300 will
go through pharmacoinvasive strategy as stream study by doing routine coronary angiography 3 to 24 hours after successful lysis, if
lysis failed in both groups’ patient will go directly to rescue PCI. Successful lysis is defined as > 50% regression of ST segment elevation with pain relief.
Conclusion: Lysis associated with more myocardial damage, more Troponin release and less preservation of myocardial contractility
function measured by Echo by EF. Pharmacoinvasive strategy significantly reduce risk of reinfarction, need for CABG, PCI, arrhythmia,
preservation of EF and at least is as effective as 1ry PCI.